Represented VolitionRx Limited (NYSE American: VNRX) in connection with its $9 million private placement of public equity (PIPE) offering, consisting of 5 million shares of the company’s common stock at a price of $1.80 per share and a warrant to purchase up to an additional 5 million shares of common stock at a price of $3.00 per share. VolitionRx intends to use the net proceeds from the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.
Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
The Newport Beach-based deal team representing VolitionRx included Marc Alcser and Matthew Brodsky.